aTYR PHARMA INC Cash and Cash Equivalents, Period Increase (Decrease)
aTYR PHARMA INC (ATYR) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$8.46 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-14
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $1.54M.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$10.00M, a 1283.08% decline year-over-year.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$8.59M.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $12.28M.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for fiscal 2018 was $1.87M.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$17.30M.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$14.64M, a 137.41% decline from fiscal 2015.
- aTYR PHARMA INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was $39.13M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$8.46M 10-Q · filed 2019-08-14 | -$17.04M derived: sum of 3 quarters · filed 2019-08-14 | -$4.76M derived: sum of 4 quarters · filed 2019-08-14 |
| 2019-03-31 | -$10.00M 10-Q · filed 2019-05-14 | -$18.58M derived: sum of 2 quarters · filed 2019-05-14 | -$6.31M derived: sum of 3 quarters · filed 2019-05-14 | -$8.97M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-12-31 | -$8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $3.69M derived: sum of 2 quarters · filed 2019-03-26 | $1.03M derived: sum of 3 quarters · filed 2019-08-14 | $1.87M 10-K · filed 2019-03-26 |
| 2018-09-30 | $12.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $9.61M derived: sum of 2 quarters · filed 2019-08-14 | $10.46M 10-Q · filed 2018-11-14 | $1.78M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-06-30 | -$2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$1.82M 10-Q · filed 2019-08-14 | -$10.49M derived: sum of 3 quarters · filed 2019-08-14 | -$16.64M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $845.00K 10-Q · filed 2019-05-14 | -$7.83M derived: sum of 2 quarters · filed 2019-05-14 | -$13.98M derived: sum of 3 quarters · filed 2019-05-14 | -$6.96M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | -$8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$14.82M derived: sum of 2 quarters · filed 2019-03-26 | -$7.81M derived: sum of 3 quarters · filed 2019-03-26 | -$17.30M 10-K · filed 2019-03-26 |
| 2017-09-30 | -$6.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $865.00K derived: sum of 2 quarters · filed 2018-11-14 | -$8.62M 10-Q · filed 2018-11-14 | -$4.57M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-06-30 | $7.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$2.47M 10-Q · filed 2018-08-14 | $1.58M derived: sum of 3 quarters · filed 2019-03-26 | -$7.28M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-03-31 | -$9.49M 10-Q · filed 2018-05-15 | -$5.43M derived: sum of 2 quarters · filed 2019-03-26 | -$14.29M derived: sum of 3 quarters · filed 2019-03-26 | -$25.20M derived: sum of 4 quarters · filed 2019-03-26 |
| 2016-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$4.80M derived: sum of 2 quarters · filed 2019-03-26 | -$15.71M derived: sum of 3 quarters · filed 2019-03-26 | -$14.64M 10-K · filed 2019-03-26 |
| 2016-09-30 | -$8.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$19.77M derived: sum of 2 quarters · filed 2017-11-14 | -$18.69M 10-Q · filed 2017-11-14 | -$25.72M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-06-30 | -$10.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$9.83M 10-Q · filed 2017-08-14 | -$16.86M derived: sum of 3 quarters · filed 2018-03-20 | -$19.88M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-03-31 | $1.07M 10-Q · filed 2017-05-11 | -$5.95M derived: sum of 2 quarters · filed 2018-03-20 | -$8.97M derived: sum of 3 quarters · filed 2018-03-20 | -$413.00K derived: sum of 4 quarters · filed 2018-03-20 |
| 2015-12-31 | -$7.03M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$10.04M derived: sum of 2 quarters · filed 2018-03-20 | -$1.49M derived: sum of 3 quarters · filed 2018-03-20 | $39.13M 10-K · filed 2018-03-20 |
| 2015-09-30 | -$3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $5.54M derived: sum of 2 quarters · filed 2016-11-14 | $46.15M 10-Q · filed 2016-11-14 | $41.32M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $8.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $49.17M 10-Q · filed 2016-08-10 | $44.33M derived: sum of 3 quarters · filed 2017-03-16 | $38.43M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $40.61M 10-Q · filed 2016-05-11 | $35.78M derived: sum of 2 quarters · filed 2017-03-16 | $29.88M derived: sum of 3 quarters · filed 2017-03-16 | $30.00M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | -$4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$10.74M derived: sum of 2 quarters · filed 2017-03-16 | -$10.62M derived: sum of 3 quarters · filed 2017-03-16 | -$22.56M 10-K · filed 2017-03-16 |
| 2014-09-30 | -$5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$5.78M derived: sum of 2 quarters · filed 2015-11-10 | -$17.72M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$11.82M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$11.94M 10-Q · filed 2015-06-18 | |||
| 2013-12-31 | $32.78M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |